Text Size

New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma

This study is not yet open for participant recruitment.
Verified August 2010 by Hadassah Medical Organization
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01174537
First received: August 2, 2010
Last updated: NA
Last verified: August 2010
History: No changes posted
  Purpose

Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression. The study will measure progression-free disease and posits that it will be extended.


Condition Intervention Phase
Glioblastoma
Sarcoma
Neuroblastoma
 Biological: New Castle Disease Virus
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: at least 1 year ] [ Designated as safety issue: No ]
    Measure progression-free survival of patients receiving New Castle Virus


Estimated Enrollment: 30
Study Start Date: September 2010
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: New Castle Disease Virus
    Patients will receive IV 1*10^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
Detailed Description:

Present therapeutic regimes have not much improved the survival of patients with metastatic cancer. Therapeutic cancer vaccines are a form of immunotherapy designed to educate the immune system to recognise tumor cells as foreign rather than self. New Castle Virus (NDV) has a long history as a broad system oncolytic that can destroy tumor cells and stimulate the immune system. Up to 30 patients suffering from recurrent, refractory Glioblastoma Multiforme, soft an bone sarcomas and disseminated neuroblastoma will be enrolled in this trial and receive daily doses of NDV at least 5 days a week for a minimum of a year or until disease progression.

  Eligibility

Ages Eligible for Study:   3 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Evidence of progressive disease in the above categories evaluated by standard tumor staging.
  • Histologically confirmed diagnosis.
  • Failure of conventional anti- cancer modalities.despite optimal application of all relevant available anti- cancer modalities.
  • Age between 3 and 75 years old.
  • Liver function tests less than twice the normal, renal function no more than 20% reduction and white cell and platelets count no more than 30% reduction.
  • Karnofsky performance status of 50% or greater
  • A written informed consent understood and signed by the patient and by a spouse, parent or guardian. In patients with GBM two signs will be required due to possible alterations of psych and understanding.

Exclusion Criteria:

  • Not fulfilling any of the above criteria
  • Moribund patients or patients with life- expectancy < 3 months
  • Karnofksy performance status < 50%
  • Pregnant or lactating women
  • Active local or systemic infections requiring treatment
  • Patients receiving other investigational agents
  • History of allergy to egg ova-albumin.
  • Co-morbidity or life- threatening clinical condition other than the basic cancer
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01174537

Contacts
Contact: Reuven Or, MD 00 972 2 6776561 reuvenor@hadassah.org.il
Contact: Liliane Dray, BA 00 972 2 6777260 lilane@hadassah.org.il

Locations
Israel
Hadassah Medical Organization Not yet recruiting
Jerusalem, Israel, 91120
Contact: Reuven Or, MD     00 972 2 6776561     reuvenor@hadassah.org.il    
Contact: Liliane Dray, BA     00 972 2 6777260     lilane@hadassah.org.il    
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Reuven Or, MD Hadassah Medical Organization
  More Information

Publications:

Responsible Party: ReuvenOr, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT01174537     History of Changes
Other Study ID Numbers: NDV-HUJ-HMO-CTIL
Study First Received: August 2, 2010
Last Updated: August 2, 2010
Health Authority: Israel: Ministry of Health

Keywords provided by Hadassah Medical Organization:
NDV
Metastatic
Refractory
Cancer
 Progression-free
survival
recurrent

Additional relevant MeSH terms:
Glioblastoma
Neuroblastoma
Sarcoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
 Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Connective and Soft Tissue

ClinicalTrials.gov processed this record on May 16, 2013